EMCC European Monitoring Centre on Change

EMCC dossier on the biomedical healthcare sector – Additional sources of information

This document lists further sources of information on the commerce sector that may be of interest to the reader.

EuropaBio website, http://www.europabio.org/

  • The website for the European Association for Bioindustries (EuropaBio) is the primary source for information on biotechnology in Europe. It contains a dedicated section on healthcare biotechnology that focuses on the technological, market and regulatory developments and ethical issues. The EuropaBio healthcare manifesto – the organisation’s main priorities in terms of policy development and regulatory implementation – is available at http://www.healthcare-manifesto.org/intro.html.

European Commission website on biotechnology: http://ec.europa.eu/biotechnology/index_en.htm

  • An important source of information on regulatory and policy issues, the website contains information on: genetically modified organisms, research and development, the competitiveness of the industry in Europe, patenting biotechnological inventions, ethical and trade issues, and biotechnology in developing countries. It also provides access to a range of publications on biotechnology and medical devices.

The Biotechnology for Europe Study website: http://bio4eu.jrc.es/index.html

  • This website outlines the findings of a study on the consequences, opportunities and challenges of modern biotechnology for Europe. The study focuses on three key applications: human and animal health, primary production and agro-food and industrial processes, and energy and environment. A synthesis report provides data on the main economic developments in the European biomedical industry, including a comparison of the economic significance and performance of the sector in Europe as against the US.

OECD biotechnology website: http://www.oecd.org/topic/0,3373,en_2649_37437_1_1_1_1_37437,00.html

  • The website contains provides access to statistical data on national biotechnology industries. In addition, a range of reports on issues such as intellectual property, innovation in the biotechnology industry, biosecurity and the concept of ‘bioeconomy’ can be downloaded from this website.

Deloitte life sciences website: http://www.deloitte.com/dtt/section_node/0,1042,sid%253D2221,00.html

  • This site contains information on developments in the life science industry. Among the issues discussed is the market prospects of personalised medicines and the convergence between biotechnology companies and pharmaceutical companies. In addition to reports, the website also provides access to audiovisual material, including podcasts. While the site’s content focuses on business strategies for pharmaceutical companies, there is also information relevant for the biomedical sector.

EurActiv website, section on life sciences and biotechnology: http://www.euractiv.com/en/science/life-sciences-biotechnology/article-117517

  • EurActiv.com is an independent media portal dedicated to EU affairs. The section on life sciences and biotechnology focuses on policy and regulatory developments at the European level. It also provides links to official EU documents and the sites of key actors (governments, industry federations, NGOs etc.).

The supply and demand for skills in the biotechnology sector (report for Irish development advisory board): http://www.skillsireland.ie/press/reports/pdf/egfsn0309_biotechnology_sector_skills.pdf

  • Carried out in 2003, this study aimed to identify the potential growth of the biotechnology sector in Ireland, to quantify the levels of skills that would be required to realise this growth and to review the projected supply of these skills over the period 2004–2010. It is intended to inform the policies of stakeholders – education providers, government departments and industrial development agencies. In addition, it analyses a number of successful biotechnology clusters identifies the common factors underpinning their success. It identifies the key challenge for Ireland as being a shortfall in scientific skills.

Back on track: The European perspective (report from Ernst & Young): http://biotech.pd.cnr.it/docs/Imprese_biotech_in_europa_2006.pdf

  • This report provides a short overview of the main developments in the European biotechnology sector with a focus on financial aspects. It finds that after years of relatively stagnant results, the sector’s performance has improved on several fronts. The industry is investing strongly in the future, and is funding large increases in research and development.

Innovation and industry structure in the biomedical industry: Some preliminary results: http://eprints.vu.edu.au/archive/00000101/01/wp17_2004_rasmussen.pdf

  • This article by Bruce Rasmussen covers such issues as market developments, value chains, cluster theory, and innovation in the biomedical industry. It maintains that innovation in the pharmaceutical industry (new technologies, and especially biotechnology) have made the industry structure more complex.

Innovation and competitiveness in European biotechnology (enterprise papers from European Commission website): http://europa.eu.int/comm/enterprise/library/enterprise-papers/paper7.htm

  • The report analyses the state of innovation and production systems in European biotechnology and assesses the variables that affect industrial growth and competitiveness in biotechnology. It concludes that the European research system in the life sciences and in biotechnology is too fragmented, which may be due to regulatory, entrepreneurial, fiscal and financial factors and an inadequate supply of cutting-edge scientific research. If this final issue is a factor, it problem could be addressed through greater fundings of research, greater diversity of funding sources, and more integration of research with teaching, clinical research and medical practice.
Useful? Interesting? Tell us what you think. Hide comments

Eurofound welcomes feedback and updates on this regulation

Add new comment